http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EC-SP20032315-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b1d08574feb5fc8275d94ffbd43d4cc0 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F9-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-662 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-66 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F9-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-22 |
| filingDate | 2020-06-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e5758c47ccc3cf6cce1d98ffe2336fb5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_306ea7c73733db1c54b545136bedd1b4 |
| publicationDate | 2020-07-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EC-SP20032315-A |
| titleOfInvention | TRIPHENYLPHOSPHONIUM DERIVATIVE COMPOUNDS TO ERADICATE CANCER STEM CELLS |
| abstract | Tri-phenyl-phosphonium (TPP) is a non-toxic chemical moiety that functionally behaves as a mitochondrial target binding signal in living cells. TPP-related compounds can be used to target mitochondria in cancer stem cells (CSCs), and can be used to treat and / or prevent tumor recurrence, metastasis, drug resistance, and / or radiation therapy resistance, as well as well as for anticancer therapies. Several TPP-related compounds that are validated for the inhibition of oxygen consumption (OCR) were non-toxic and had little or no effect on ATP production in normal human fibroblasts. However these compounds selectively target adherent "bulk" cancer cells. These compounds also inhibit the spread of CSCs in suspension. TPP-related compounds provide a novel chemical strategy to effectively target both i) "bulk" cancer cells and ii) CSC, while specifically minimizing or avoiding side effects other than what is desired in normal cells, among other therapies. tools. |
| priorityDate | 2017-11-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
| Predicate | Subject |
|---|---|
| isDiscussedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID414813019 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5241824 |
Total number of triples: 23.